|
|
Article: Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus RSV Infection.
- Article from:
- Blood Weekly
- Article date:
- January 22, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cubist Pharmaceuticals, Inc., (Nasdaq: CBST), a leading acute care biopharmaceutical company, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that they have formed a strategic collaboration to develop and commercialize AlnylamEs ALN-RSV program. The RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies (see also Cubist Pharmaceuticals, Inc. and Alnylam ...
Related newspaper, magazine, and journal articles:
|
|
Article: Alnylam Pharmaceuticals Reports First Quarter 2009 ...
Blood Weekly;
May 28, 2009 ;
700+ words
...Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ... company highlights (see also Alnylam Pharmaceuticals, Inc.). "This past quarter ... Institutes of Health (NIH), Cubist Pharmaceuticals, Inc., Biogen Idec, InterfeRx ...
|
|